Résultats de la recherche - Mazyar Shadman

  • Résultat(s) 1 - 2 résultats de 2
Affiner les résultats
  1. 1
    Minimal residual disease status predicts outcomes in patients with follicular lymphoma treated with chemo-immunotherapy on the SWOG S0016 trial

    Minimal residual disease status predicts outcomes in patients with follicular lymphoma treated with chemo-immunotherapy on the SWOG S0016 trial par Alexey V. Danilov, Hongli Li, Mazyar Shadman, Lisa Rimsza, Ahmad Zebari, Sonali M. Smith, Michael LeBlanc, Jonathan W. Friedberg, Christopher Carlson, Joo Y. Song

    Publié 2025-07-01

    Not available.

    Accéder au texte intégral
    Article

    Ajouter aux favoris
    Enregistré dans:
  2. 2
    Efficacy of zanubrutinib versus acalabrutinib for relapsed or refractory chronic lymphocytic leukemia (R/R CLL): a matching-adjusted indirect comparison (MAIC)

    Efficacy of zanubrutinib versus acalabrutinib for relapsed or refractory chronic lymphocytic leukemia (R/R CLL): a matching-adjusted indirect comparison (MAIC) par Mazyar Shadman, Jennifer R. Brown, Rhys Williams, Leyla Mohseninejad, Keri Yang, Pal Rakonczai, Nicole Lamanna, Sheng Xu, Aileen Cleary Cohen, Susan M. O’Brien, Alessandra Tedeschi, Constantine S. Tam

    Publié 2025-07-01

    Background: There are no head-to-head studies comparing the efficacy of the Bruton tyrosine kinase inhibitors, zanubrutinib and acalabrutinib, in relapsed or refractory chronic lymphocytic leukemia (R/R CLL). Objective: To compare the relative efficacy of zanubrutinib and acalabrutinib in R/R CLL us...

    Description complète

    Accéder au texte intégral
    Article

    Ajouter aux favoris
    Enregistré dans:

Outils de recherche: